rs8192870 — CYP7A1 CYP7A1 intron 1 variant

Intronic variant in the rate-limiting bile acid synthesis gene; T allele carriers show reduced LDL-lowering response to statins and elevated cardiovascular risk.

See your personal result for CYP7A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP7A1 — The Bile Acid Gate That Controls Your Cholesterol Set Point

Your liver disposes of excess cholesterol by converting it into bile acids — detergent-like molecules that emulsify fat in the gut and are then recycled through the enterohepatic circulation. The enzyme that controls the entry point of this pathway, cholesterol 7α-hydroxylase (CYP7A1), is the rate-limiting step. More CYP7A1 activity means more cholesterol is pulled out of the blood and converted to bile acids; less activity means cholesterol accumulates. The rs8192870 variant tags a haplotype in the CYP7A1 gene's first intron that influences how much of this enzyme the liver produces.

The Mechanism

rs8192870 is an intronic variant in CYP7A1 (chromosome 8, position 58,499,507 on GRCh38) that does not itself change the CYP7A1 protein. Instead, it is in strong linkage disequilibrium11 linkage disequilibrium
Linkage disequilibrium (LD) means two variants are inherited together so often that knowing one predicts the other; D' > 0.90 here (D' > 0.90) with the functional promoter variant rs3808607 and other regulatory SNPs that directly alter CYP7A1 gene expression in liver hepatocytes. Carriers of the T allele at rs8192870 tend to carry the lower-expression CYP7A1 haplotype, which reduces the liver's capacity to convert cholesterol into bile acids. Less bile acid synthesis means less hepatic LDL receptor up-regulation and higher circulating LDL-cholesterol.

A 2018 study published in Circulation: Genomic and Precision Medicine 22 Hegele et al. Interactions between regulatory variants in CYP7A1 promoter and enhancer regions regulate CYP7A1 expression. Circ Genom Precis Med, 2018 showed that two CYP7A1 regulatory variants, both in strong LD with rs8192870, together explain more than two orders of magnitude variation in hepatic CYP7A1 mRNA levels across human liver donors — a dramatic range that maps onto measurable LDL-C differences in population studies.

The Evidence

A study of 1,462 Mexican mestizo individuals 33 Vargas-Alarcón et al. CYP7A1 gene polymorphisms associated with LDL-cholesterol and subclinical atherosclerosis. Biomolecules and Biomedicine, 2025 found that rs8192870 T allele carriers had significantly increased risk of subclinical atherosclerosis (dominant model OR 1.44, p=0.011) compared to GG homozygotes. TT homozygotes showed median LDL-C of 145 mg/dL versus 121 mg/dL in GG carriers (p=0.003 among atherosclerosis cases).

The statin-response impact is well-documented. In 107 Chinese Han patients treated with atorvastatin, 44 Zhang et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther, 2012 TT homozygotes achieved 35.3% LDL reduction versus only 27.9% in GG/GT carriers (p=0.021). This paradoxical finding — T allele carriers who have lower baseline CYP7A1 activity actually respond better to statins — is explained mechanistically: statins block HMG-CoA reductase, which relieves negative feedback on CYP7A1. In low-activity T allele carriers, there is more room for CYP7A1 to be upregulated by the statin, translating to greater relative LDL reduction. However, those same individuals have higher untreated LDL-C, meaning they are more likely to need a statin in the first place.

An earlier pharmacogenomics study of 324 hypercholesterolemic patients 55 Kajinami et al. CYP7A1 promoter polymorphism interacts with APOE genotype in LDL-lowering atorvastatin response. Arterioscler Thromb Vasc Biol, 2005 found that combined CYP7A1 and APOE variant status can explain the difference between a 40% LDL reduction and only a 31% reduction on the same statin dose, highlighting the importance of knowing your CYP7A1 haplotype alongside APOE status.

Practical Actions

For GG individuals with normal CYP7A1 activity, the key insight is that your cholesterol disposal pathway is functioning well — dietary interventions that work through the bile acid pathway (plant sterols, beta-glucan, bile acid sequestrants) are more likely to produce meaningful LDL reductions. For GT and TT individuals with reduced CYP7A1 output, the liver's cholesterol-to-bile-acid conversion is blunted; this elevates LDL-C set points and reduces cholesterol absorption inhibitors' efficacy. Statin therapy remains highly effective — statins upregulate CYP7A1 through FXR pathway suppression, partially compensating for the genotype-driven deficit.

Monitoring LDL-C and non-HDL-C fasting panels is particularly informative for T allele carriers because their elevated set point may not be apparent from a single snapshot.

Interactions

rs8192870 is in strong LD (D' > 0.90) with the CYP7A1 promoter variant rs3808607 (−204A>C) and with the downstream enhancer variant rs9297994. The two-SNP model combining rs3808607 and rs9297994 is a more powerful predictor of hepatic CYP7A1 mRNA than any single variant alone. Users who also carry the APOE ε4 allele (rs429358 CC) may experience compounded LDL elevation because both CYP7A1 reduced activity and APOE4 impair LDL-receptor-mediated clearance through independent mechanisms — a combination documented by Kajinami et al. (2005) to result in the lowest statin LDL response of any genotype combination studied.

Drug Interactions

atorvastatin reduced_efficacy literature
simvastatin reduced_efficacy literature

Nutrient Interactions

dietary cholesterol altered_metabolism
plant sterols altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Bile Acid Synthesis Normal

Standard CYP7A1 enzyme activity with efficient cholesterol-to-bile-acid conversion

You carry two copies of the G allele, the major allele associated with normal to higher CYP7A1 promoter haplotype activity. Your liver's cholesterol 7α-hydroxylase enzyme converts cholesterol into bile acids at a typical rate, supporting normal LDL-cholesterol clearance through the classic bile acid synthesis pathway. About 55% of people globally share this GG genotype. Population studies show GG individuals have lower median LDL-C compared to T allele carriers and are at baseline risk for LDL-related cardiovascular outcomes.

GT Reduced Bile Acid Synthesis Intermediate

One T allele moderately reduces CYP7A1 bile acid synthesis capacity and slightly elevates LDL-C

The T allele at rs8192870 tags a lower-activity CYP7A1 haplotype that reduces hepatic cholesterol 7α-hydroxylase expression. Because CYP7A1 is the rate-limiting step in converting cholesterol to bile acids, lower enzyme output means more cholesterol remains in circulation as LDL. The effect is codominant: one copy of T produces an intermediate phenotype between the high-activity GG and low-activity TT states.

On statin therapy, this intermediate genotype may respond somewhat differently than GG individuals. Statins upregulate CYP7A1 via FXR pathway modulation, partially compensating for the reduced basal activity. Your overall LDL-lowering response to statins is likely similar to or slightly better than GG individuals on a per-milligram basis, but your untreated LDL set point may be modestly elevated.

TT Low Bile Acid Synthesis Decreased

Two T alleles substantially reduce CYP7A1 activity, elevating LDL-C and blunting dietary cholesterol clearance

The TT genotype represents the low-CYP7A1-activity extreme of this variant's dose-response curve. With both copies of the gene tagged to the lower-expression promoter haplotype, hepatic bile acid synthesis is substantially reduced. The liver compensates by up-regulating LDL receptors, but this compensation is incomplete, leaving a chronically elevated LDL-C set point that does not respond as strongly to dietary cholesterol reduction alone.

A key pharmacogenomics insight: TT individuals actually show greater relative LDL reduction on atorvastatin (35.3% vs 27.9% for GG/GT in a Chinese Han study, p=0.021). This is because statins upregulate CYP7A1 through FXR suppression — when basal CYP7A1 activity is low, there is more headroom for statin-driven induction. However, TT individuals typically start from a higher LDL-C baseline, so the absolute clinical benefit of reaching LDL targets may require higher statin doses or combination therapy.

The interaction with APOE4 (rs429358 C allele) is clinically significant: Kajinami et al. (2005) showed that CYP7A1 low-activity combined with APOE ε3/ε4 or ε4/ε4 resulted in only 31% LDL reduction on atorvastatin versus 40% in individuals with neither variant — a gap that can determine whether statin monotherapy achieves LDL targets.